![Michael Reusch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Reusch is Chief Medical Officer at Guard Therapeutics International AB since 2022.
Formerly, Dr. Reusch was Senior Director-Medical at Astellas Pharma Global Development, Inc. Dr. Reusch earned a doctorate from the University of Duisburg-Essen.
| Unternehmen | Position | Ende |
|---|---|---|
Astellas Pharma Global Development, Inc.
 Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Technik-/Wissenschafts-/F&E-Leiter | - |
| DISRUPTIVE PHARMA AB | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 3 |
|---|---|
University of Duisburg-Essen
 University of Duisburg-Essen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Guard Therapeutics International AB
 Guard Therapeutics International AB Pharmaceuticals: MajorHealth Technology Develops medicine for oxidative stress and acute kidney damage | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
